FTC urged to reinstate Opana ER pay-for-delay case against Impax

Washington, D.C. (October 16, 2018) -- A settlement agreement between Endo Pharmaceuticals and Impax Laboratories violated the antitrust law, an attorney for the Federal Trade Commission argued Thursday, seeking to reinstate a complaint against generic drugmaker Impax that was dismissed by an in-house judge in May.  ...

Related Sections